How Much Does Crestor (Rosuvastatin) Cost in Idaho in 2026?

Idaho Retail Pricing: Brand vs. Generic Rosuvastatin

The gap between brand-name Crestor and generic rosuvastatin in Idaho is striking. AstraZeneca's list price for brand Crestor sits near $290 per month in 2026, but the generic version averages roughly $15 per month at Idaho retail pharmacies. That price difference exceeds 90%.

Generic rosuvastatin became available after Crestor's patent expiration, and multiple manufacturers now produce it. Idaho pharmacies including Albertsons, Fred Meyer, Walgreens, and independent locations carry generic rosuvastatin at competitive cash-pay rates. Prices can vary by $5 to $10 between pharmacies in the same city, so comparing quotes from two or three locations is worth the effort. Pharmacy discount platforms like GoodRx and RxSaver frequently list rosuvastatin 10 mg or 20 mg tablets at $8 to $18 for a 30-day supply at Idaho locations.

The FDA-approved prescribing information for Crestor lists doses from 5 mg to 40 mg daily. Most patients prescribed rosuvastatin for primary ASCVD prevention start at 10 mg or 20 mg. The 40 mg dose is reserved for patients who do not reach their LDL-C target on lower doses, and it carries a higher risk of myopathy. At the generic tier, dose strength has minimal impact on out-of-pocket cost in Idaho. A 30-day supply of 5 mg costs nearly the same as 20 mg at most pharmacies.

Idaho Medicaid and Crestor Coverage

Idaho Medicaid does not include Crestor on its preferred drug list as of 2026. Patients enrolled in Idaho Medicaid who need statin therapy are typically directed toward preferred alternatives such as atorvastatin or simvastatin, both available as low-cost generics.

If a prescribing physician determines that rosuvastatin is medically necessary (for example, due to documented intolerance to atorvastatin or failure to reach LDL-C goals on other statins), a prior authorization request can be submitted to Idaho Medicaid. The 2018 ACC/AHA cholesterol guideline recommends high-intensity statin therapy for patients with clinical ASCVD, and rosuvastatin 20 mg to 40 mg qualifies as high-intensity treatment. Documentation of statin intolerance or therapeutic failure on a preferred agent strengthens the prior authorization case.

Idaho expanded Medicaid in 2020 under Proposition 2, broadening eligibility to adults earning up to 138% of the federal poverty level. Enrollees who were previously uninsured gained formulary drug access, but Crestor's exclusion from the preferred list means out-of-pocket costs or a switch to a formulary statin remain the most common paths. Generic rosuvastatin may be covered with a prior authorization even when brand Crestor is not. Patients should ask their pharmacy to run the generic NDC through Idaho Medicaid before assuming the drug is inaccessible.

Commercial Insurance Coverage in Idaho

Most commercial insurance plans sold through Your Health Idaho (the state exchange) and employer-sponsored plans cover generic rosuvastatin at a Tier 1 or Tier 2 copay. Typical copays range from $0 to $15 per month for generic rosuvastatin under plans from Blue Cross of Idaho, Regence BlueShield, SelectHealth, and PacificSource.

Brand-name Crestor, when covered at all, sits at Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays or coinsurance between $40 and $100 per month. Some plans require step therapy, meaning the patient must try and document inadequate response to a preferred generic statin before the insurer will approve brand Crestor.

The Affordable Care Act classifies statins for adults aged 40 to 75 with cardiovascular risk factors as a preventive service under USPSTF Grade B recommendation. Plans subject to ACA preventive-service mandates must cover at least one statin at $0 cost-sharing. In practice, this means generic atorvastatin or rosuvastatin often carries no copay for qualifying patients. Idaho residents should check whether their plan applies the USPSTF statin recommendation to rosuvastatin specifically or only to atorvastatin.

For Medicare Part D enrollees in Idaho, generic rosuvastatin is widely covered. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025), even patients taking multiple branded medications will see total annual drug spending capped, though generic rosuvastatin alone is unlikely to approach that threshold.

Compounded Rosuvastatin in Idaho: Legal Status and Access

Licensed 503A compounding pharmacies in Idaho can legally prepare rosuvastatin formulations based on individual patient prescriptions. This is legal under both federal law (FDA Section 503A of the FD&C Act) and Idaho Board of Pharmacy regulations.

A 503A pharmacy compounds a medication for a specific patient with a valid prescription. This differs from 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions. In Idaho, 503A compounding of rosuvastatin is the applicable pathway.

Compounded rosuvastatin may appeal to patients who need a non-standard dose, a liquid suspension (useful for patients with swallowing difficulties), or a formulation free of specific inactive ingredients that cause allergic reactions. Pricing varies by pharmacy, but compounded versions can sometimes cost less than commercial generics depending on the compounding pharmacy's sourcing and markup.

Patients considering compounded rosuvastatin should confirm that the pharmacy holds a current Idaho Board of Pharmacy compounding license and follows USP 795 standards for non-sterile compounding. The prescribing clinician must write a prescription specifying the compounded formulation. A standard generic tablet prescription cannot be unilaterally converted to a compounded product by the pharmacy.

Telehealth Prescribing of Rosuvastatin in Idaho

Idaho permits telehealth prescribing of rosuvastatin statewide. The Idaho Telehealth Access Act (Idaho Code § 54-5707) allows licensed prescribers to establish a patient-provider relationship and prescribe medications via audio-video telehealth visits. Rosuvastatin is not a controlled substance, so it does not face the additional prescribing restrictions that apply to Schedule II through V drugs.

Telehealth platforms operating in Idaho can prescribe rosuvastatin after reviewing lipid panels and cardiovascular risk factors. A standard initial evaluation includes fasting lipid panel results (or recent non-fasting lipid panel with direct LDL-C measurement), review of cardiovascular risk using the Pooled Cohort Equations or similar validated calculator, and assessment for contraindications including active liver disease or pregnancy.

For Idaho residents in rural areas, telehealth removes a significant access barrier. According to the Idaho Department of Health and Welfare, 33 of Idaho's 44 counties are classified as rural, and many lack a local cardiologist or endocrinologist. Telehealth enables a specialist or primary care clinician in Boise, Meridian, or out of state (if licensed in Idaho) to prescribe rosuvastatin and monitor follow-up labs for patients in communities like Salmon, Challis, or Grangeville.

Follow-up visits to check liver enzymes (ALT) and a repeat lipid panel are typically recommended 4 to 12 weeks after starting rosuvastatin or after a dose change. These follow-up labs can be drawn at any local lab, with results reviewed via a telehealth visit. The 2018 ACC/AHA guideline recommends fasting lipid panel measurement 4 to 12 weeks after statin initiation to assess adherence and therapeutic response.

Clinical Evidence Supporting Rosuvastatin Use

Rosuvastatin is among the most potent statins by milligram. At the 10 mg dose, rosuvastatin typically lowers LDL-C by 45% to 52%, while at 20 mg, reductions reach 48% to 55%. The 40 mg dose can reduce LDL-C by more than 55% in some patients.

The landmark JUPITER trial (N=17,802) randomized patients with LDL-C below 130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP ≥ 2.0 mg/L) to rosuvastatin 20 mg or placebo. The trial was stopped early at a median of 1.9 years because rosuvastatin reduced the primary composite endpoint (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) by 44% (HR 0.56 to 95% CI 0.46 to 0.69, P<0.00001). LDL-C dropped by 50% in the rosuvastatin group, and hsCRP fell by 37%.

JUPITER changed practice. It demonstrated that rosuvastatin reduced cardiovascular events even in patients whose baseline LDL-C would not have triggered statin therapy under older guidelines. The trial's results directly influenced the 2013 ACC/AHA cholesterol guideline's shift toward risk-based (rather than purely LDL-target-based) statin prescribing.

The METEOR trial showed that rosuvastatin 40 mg slowed the progression of carotid intima-media thickness (CIMT) compared with placebo in patients with subclinical atherosclerosis, as reported in JAMA. While CIMT is a surrogate endpoint, the trial provided evidence that rosuvastatin could affect the atherosclerotic disease process in lower-risk individuals.

Dr. Paul Ridker, the principal investigator of JUPITER, stated: "These data provide evidence that statin therapy may have a role in primary prevention among individuals who are not currently candidates for treatment under existing guidelines." That observation remains relevant for Idaho clinicians making prescribing decisions for patients with borderline cardiovascular risk.

How to Lower Your Rosuvastatin Cost in Idaho

Several strategies can reduce out-of-pocket spending on rosuvastatin in Idaho.

Always fill the generic. Unless a clinician has a specific reason to prescribe brand Crestor, generic rosuvastatin provides the identical active ingredient at a fraction of the cost. Idaho law permits pharmacists to substitute generics unless the prescriber writes "dispense as written."

Use pharmacy discount cards. GoodRx, RxSaver, and similar platforms are accepted at most Idaho pharmacies, including chains and many independents. These programs negotiate discounted cash prices and are free to use. They may beat insurance copays for generic rosuvastatin.

Check the USPSTF preventive statin benefit. If you are 40 to 75 years old with at least one cardiovascular risk factor and your 10-year ASCVD risk is 10% or greater, ACA-compliant plans must cover a statin with no cost-sharing. Confirm with your insurer that rosuvastatin (not just atorvastatin) qualifies under this benefit on your specific plan.

Ask about 90-day fills. Many Idaho pharmacies and mail-order services offer 90-day supplies at a lower per-unit cost than three separate 30-day fills. For a maintenance medication like rosuvastatin, 90-day dispensing also reduces pharmacy trips.

Manufacturer programs. AstraZeneca's savings card applies to brand Crestor only and may reduce copays for commercially insured patients. It does not apply to government insurance (Medicaid, Medicare, Tricare). For generic rosuvastatin, manufacturer savings cards are not available because multiple generic companies produce the drug without branded savings programs.

Patient assistance programs. Uninsured or underinsured Idaho residents may qualify for patient assistance through NeedyMeds, RxAssist, or Idaho's 211 resource line. Some independent pharmacies in Idaho also offer flat-rate generic programs where rosuvastatin 30-day supply costs $4 to $10.

Side Effects and Monitoring Considerations

Common side effects of rosuvastatin include headache, myalgia, abdominal pain, nausea, and asthenia. In clinical trials, myalgia occurred in approximately 3% to 5% of patients. Serious adverse events are rare but include rhabdomyolysis, hepatotoxicity, and new-onset diabetes.

The JUPITER trial identified a statistically significant increase in physician-reported diabetes in the rosuvastatin group compared to placebo (3.0% vs. 2.4%, P=0.01), as noted in a secondary analysis. A 2010 Lancet meta-analysis of 13 statin trials (N=91,140) found that statin therapy was associated with a 9% relative increase in incident diabetes (OR 1.09 to 95% CI 1.02 to 1.17). The absolute risk increase is small, and for most patients the cardiovascular benefit outweighs the diabetes risk.

Idaho clinicians should order baseline hepatic transaminases before starting rosuvastatin. The FDA label recommends checking liver enzymes if symptoms suggest hepatotoxicity (unexplained fatigue, anorexia, jaundice, dark urine). Routine periodic liver enzyme monitoring is no longer recommended by the 2018 ACC/AHA guideline in asymptomatic patients, a change from older practice patterns.

Patients of Asian descent may have higher rosuvastatin plasma concentrations at standard doses. The FDA label recommends a starting dose of 5 mg in this population. Idaho prescribers should account for this pharmacokinetic difference during initial dosing.

Idaho-Specific Pharmacy and Regulatory Notes

Idaho's Board of Pharmacy licenses all retail, mail-order, and compounding pharmacies operating in the state. Out-of-state mail-order pharmacies must hold a nonresident pharmacy license to ship rosuvastatin to Idaho addresses. Patients using telehealth platforms that partner with out-of-state pharmacies should verify this licensure.

Idaho does not impose a state-level drug importation program as of 2026. Importing rosuvastatin from Canadian or other international pharmacies remains federally prohibited for individuals, though enforcement against personal-use importation is historically limited. The FDA's position is that imported drugs are unapproved and potentially unsafe.

The Idaho Legislature has not enacted statin-specific prescribing restrictions beyond standard scope-of-practice laws. Nurse practitioners and physician assistants in Idaho can prescribe rosuvastatin independently under their respective practice acts.